CG Oncology (CGON) vs Kodiak Sciences (KOD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kodiak Sciences (KOD) has outperformed CG Oncology (CGON) over the past year, gaining 540.1% versus a gain of 64.2%. Kodiak Sciences is the larger company by market cap ($5.72 billion vs $5.53 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | KOD |
|---|---|---|
| Share price | $62.38 | $91.08 |
| Market cap | $5.53B | $5.72B |
| 1-day change | -1.98% | -1.36% |
| YTD return | +50.24% | +225.75% |
| 1-year return | +64.16% | +540.06% |
| 5-year return | — | -18.66% |
| EPS (TTM) | $-2.69 | $-4.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | — |
| Revenue growth (YoY) | +254.70% | — |
| Net income (latest FY) | $-161.00M | $-229.97M |
| Operating margin | -4722.13% | — |
| Net margin | -3985.02% | — |
| 52-week high | $80.97 | $104.00 |
| 52-week low | $35.80 | $10.94 |
| Distance from 52-week high | -22.96% | -12.42% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +46.01% | +28.10% |
| Average volume | 891.79K | 1.57M |
| Shares outstanding | 88.64M | 62.85M |
| Employees | 142 | 141 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed CGON by 475.9 percentage points over the past year.
- The two companies sit in different sectors: CG Oncology in Healthcare and Kodiak Sciences in Health Care.
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Healthcare · Biotechnology · 142 employees
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
CGON vs KOD FAQ
Which is bigger, CG Oncology or Kodiak Sciences?
Kodiak Sciences (KOD) is larger, with a market capitalization of $5.72B compared with $5.53B for CG Oncology (CGON).
Which stock has performed better over the past year, CGON or KOD?
KOD returned +540.06% over the past 12 months, compared with +64.16% for CGON (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Kodiak Sciences in the same industry?
No. CG Oncology is in the Healthcare sector, while Kodiak Sciences is in Health Care.